Title : Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C.

Pub. Date : 2017 Feb 18

PMID : 28261382






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSION: Both TVR- and SMV-based triple therapies can be successfully used to treat patients aged 66 years or older with genotype 1b chronic hepatitis C. Genotyping of the IL28B indicates a potential to achieve SVR in these difficult-to-treat elderly patients. Simeprevir interferon lambda 3 Homo sapiens